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Activation of phosphoinositide 3-kinase (PI3K) is required for B cell proliferation and sur-
vival. PI3K signaling also controls key aspects of B cell differentiation. Upon engagement
of the B cell receptor (BCR), PI3K activation promotes Ca2+ mobilization and activation of
NFκB-dependent transcription, events which are essential for B cell proliferation. PI3K also
initiates a distinct signaling pathway involving the Akt and mTOR serine/threonine kinases.
It has been generally assumed that activation of Akt and mTOR downstream of PI3K is
essential for B cell function. However, Akt and mTOR have complex roles in B cell fate
decisions and suppression of this pathway can enhance certain B cell responses while
repressing others. In this review we will discuss genetic and pharmacological studies of
Akt and mTOR function in normal B cells, and in malignancies of B cell origin.
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OVERVIEW OF PI3K EFFECTORS IN B CELLS
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinase
enzymes that produce 3′-phosphorylated phosphoinositides
(Okkenhaug and Fruman, 2010; Vanhaesebroeck et al., 2010; So
and Fruman, 2012). These lipids act as second messengers to
redirect cytoplasmic proteins to cellular membranes. The produc-
tion of phosphatidylinositol-3,4,5-trisphosphate (PIP3) by class I
PI3Ks is a shared response downstream of a variety of receptors
in all mammalian cell types. In B cells, class I PI3K activation is
initiated when the B cell receptor (BCR) recognizes antigen and
is augmented by CD19, a component of the B cell co-receptor.
Class I PI3K activity is necessary for BCR-dependent prolifera-
tion and is sufficient for BCR-dependent tonic survival signaling.
T cell-derived cytokines including interleukin-4 (IL-4) augment
and sustain PI3K activity during B cell growth and clonal expan-
sion. Toll-like receptor (TLR) engagement, chemokine signaling,
and cytokines (e.g., BAFF) also trigger class I PI3K activation. The
central role of PI3K activation in B cell function has prompted
detailed studies of signaling mechanisms downstream of PI3K.
Proteins recruited to the membrane through binding to PI3K
lipid products are generally termed PI3K effectors (Fruman, 2004;
Lemmon, 2008). Most effectors of class I PI3K have a pleckstrin
homology (PH) domain that binds selectively to PIP3 and/or
phosphatidylinositol-3,4-bisphosphate (PtdIns-3,4-P2). Btk and
Tec are closely related protein tyrosine kinases whose PH domains
bind with high affinity to PIP3. These kinases function in a
large protein assembly called the BCR signalosome, whose pri-
mary output is activation of phospholipase-C-gamma (PLCγ),
leading to production of diacylglycerol (DAG) and inositol-1,4,5-
trisphosphate (IP3; Fruman et al., 2000; Fruman, 2004). Together
these second messengers promote Ca2+ mobilization, protein
kinase C (PKC) activation, and ultimately the nuclear translo-
cation of NFκB transcription factors to drive B cell proliferation
(Figure 1). Loss of Btk or blockade of its binding to PIP3 reduces
the Ca2+ response, diminishes NFκB activation, and prevents pro-
ductive B cell activation. Conversely, forced activation of PKC or
NFκB restores BCR-dependent responses in B cells lacking PI3K
or Btk function. These findings suggest that signalosome assembly
and NFκB activation are the most important functional outcomes
of PI3K signaling during BCR-stimulated B cell activation. More-
over, genetic inactivation of class I PI3K in both humans and mice
causes a B cell deficiency similar to the Btk-loss phenotype (Fru-
man et al., 1999; Suzuki et al., 1999; Conley et al., 2012). Apart
from the Ca2+ signalosome, PI3K activation triggers the mem-
brane recruitment of additional protein assemblies that might also
have key functions.
Two PH domain-containing proteins linked to PI3K activity
in all cells, including B cells, are the serine/threonine kinases Akt
and phosphoinositide-dependent kinase-1 (PDK-1; Fayard et al.,
2010). The three related Akt kinases (Akt1, Akt2, Akt3; also known
as PKBα,β,γ) each contain a threonine residue in the activation
loop (T308 in Akt1) that is phosphorylated by PDK-1 in a manner
dependent on PI3K activity (Figure 1). Subsequent phosphoryla-
tion of a serine in a hydrophobic motif (S473 in Akt1) by a distinct
kinase is required for maximal Akt activation. All three Akt iso-
forms are expressed in B lineage cells and their functions appear
to be partially redundant (Calamito et al., 2010). Of the many Akt
substrates reported, the Forkhead Box, Subgroup O (FOXO) tran-
scription factors are of particular importance for B cell biology as
discussed below. Akt-mediated FOXO phosphorylation suppresses
their transcriptional activity and causes their nuclear export and
sequestration or degradation (Burgering, 2008).
The mTOR kinase is encoded by a single gene in mammals but
is the active enzyme in two distinct multi-protein complexes called
mTORC1 and mTORC2 (Figure 2; Laplante and Sabatini, 2012).
mTORC1 is defined by the raptor subunit and mTORC2 by the
rictor subunit. The main function of mTORC1 is to sense nutrients
and mitogenic signals; when conditions are favorable, mTORC1
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FIGURE 1 |This diagram of BCR/CD19-initiated signaling shows two key
outcomes of PI3K activation. PIP3 production by class IA PI3K promotes
formation of a signalosome containing Btk, BLNK, and PLCγ, leading to
hydrolysis of PI-4,5-P2 by PLCγ. The products of this reaction, DAG and IP3,
promote the activation of PKC and ultimately the nuclear translocation of
NFκB transcription factors. This pathway is essential for proliferation following
antigen recognition. A second outcome of PIP3 production is the membrane
recruitment of PDK-1 and Akt, with subsequent phosphorylation of Akt on
two distinct sites by PDK-1 and mTORC2 (mTOR in complex with rictor, see
Figure 2).
FIGURE 2 |This schematic diagram shows the components of mTORC1
and mTORC2, and the most well known substrates of the two
complexes. ULK1 (Unc51-like kinase-1) is involved in the control of
autophagy.
triggers biosynthetic pathways essential for cell growth and pro-
liferation. Akt can promote mTORC1 activation through several
mechanisms, as described in more detail below. mTORC2 activity
can be stimulated by growth factors but is nutrient-independent.
The best-described function of mTORC2 is to phosphorylate Akt
on S473. However, other kinases can phosphorylate this site in
certain conditions (Fayard et al., 2010) and mTORC2 has other
important substrates as well, including serum- and glucocorticoid-
induced kinase (SGK) and PKC as shown in Figure 2. SGK family
members have some overlapping properties with Akt isoforms, for
example the ability to phosphorylate FOXO transcription factors
(Brunet et al., 2001).
Overall, the signaling network defined by Akt and the two
mTOR complexes is a central driver of cell growth, metabolism,
and proliferation, and the activity of this network is elevated in
nearly all human cancers (Engelman et al., 2006; Liu et al., 2009).
Consequently, there has been great interest in targeting the path-
way for therapeutic benefit in cancer. In parallel, Akt and mTOR
signaling has been actively studied in the context of normal lym-
phocyte function (So and Fruman, 2012). Indeed, mTOR was first
discovered and named as the target of rapamycin, an immunosup-
pressive drug that is now used clinically to prevent organ transplant
rejection (Guertin and Sabatini, 2009). Rapamycin suppresses T
cell proliferation, promotes regulatory T cell differentiation, and
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modulates the function of innate immune cells. In this review we
describe our current knowledge of Akt and mTOR functions in B
lymphocytes.
THE Akt-FOXO AXIS IN B CELL DEVELOPMENT, ACTIVATION,
AND DIFFERENTIATION
Akt was first defined as a key PI3K effector in 1995 (Franke
et al., 1995). Within a few years, several groups had shown that
Akt is recruited to the membrane and activated downstream of
the BCR and CD19, in a manner dependent on PI3K (Aman
et al., 1998; Astoul et al., 1999; Pogue et al., 2000; Otero et al.,
2001). Subsequently, we reported that BCR signaling through PI3K
downregulates expression of FOXO target genes Rbl2 and Ccng2
(Fruman et al., 2002; Yusuf et al., 2004). These genes encode the
proteins p130 and cyclin G2, both implicated in cell cycle arrest in
non-lymphoid cells (Kops et al., 2002; Martinez-Gac et al., 2004).
Consistent with a role for FOXO factors in opposing cell cycle
progression, Akt-dependent inactivation of FOXO transcription
factors is important for optimal B cell proliferation in response to
lipopolysaccharide (LPS; Yusuf et al., 2004). It is likely that Akt has
many other substrates that play key roles in B cell biology. How-
ever, the Akt-FOXO axis has emerged as a key control point for
various aspects of B cell function.
FOXO transcription factors (FOXO1, FOXO3a, FOXO4,
FOXO6) are an evolutionarily conserved family of proteins whose
activity is tightly controlled by growth factors (Burgering, 2008).
In the absence of mitogenic signals, FOXO proteins are mainly
nuclear and direct a transcriptional program that blocks cell
cycle progression and promotes stress resistance and longevity
(Figure 3). FOXO factors can also promote expression of pro-
apoptotic genes (Fu and Tindall, 2008). Growth factor receptor
signaling inactivates FOXO through Akt-dependent phosphory-
lation on three conserved serine or threonine residues. These
phosphorylation events trigger the release of FOXO from DNA,
nuclear export, and sequestration or degradation in the cytoplasm
(Figure 3). Some of the consensus sites for Akt phosphorylation
are also substrates for SGKs, whose activity is not as tightly cou-
pled to PI3K signaling (Brunet et al., 2001). Also, FOXO function
is regulated further by acetylation and by the status of cooperat-
ing transcription factors (Calnan and Brunet, 2008). Nevertheless,
PI3K/Akt activation plays a dominant role in regulation of FOXO
activity. Both FOXO1 and FOXO3 are controlled by Akt-mediated
phosphorylation and both isoforms are expressed in B lineage cells
(Dengler et al., 2008; Hinman et al., 2009; Lin et al., 2010).
Foxo1 is an essential component of a transcription factor net-
work in pro-B cells that also includes E2A and EBF1 (Lin et al.,
2010). This study showed that E2A binds to regulatory elements
upstream of the Foxo1 gene, and that FOXO1 protein functions
together with E2A and EBF1 to induce transcription of the Pax5
gene to drive B cell commitment. An unanswered question is
how FOXO1 retains a required nuclear function in B cell prog-
enitors, which are continuously exposed to cytokines and other
signals that activate PI3K/Akt signaling. Gene knockout studies
have confirmed that the Foxo1 gene is essential for proper B cell
FIGURE 3 |This diagram illustrates the control of FOXO function by
PI3K/Akt activation. In resting B cells, FOXO factors are mainly nuclear and
direct a gene expression program favoring quiescence (cell cycle arrest,
longevity) and recirculation (trafficking through blood and lymphoid tissue). B
cell activation triggers PI3K/Akt activity, and active Akt enters the nucleus to
phosphorylate FOXO proteins on several conserved sites (noted by red dots).
This leads to nuclear export of FOXO factors that are then sequestered and/or
degraded in the cytoplasm.
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development. Using mice with a conditional allele of Foxo1,Rickert
and colleagues analyzed FOXO1 function at various stages using
different Cre deleter strains (Dengler et al., 2008). Deletion at
an early stage using Mb1-Cre causes a partial block at the pro-
B cell stage that can be attributed to impaired expression of the
interleukin-7 receptor. Deletion in late pro-B cells using Cd19-Cre
causes a block at the pre-B cell stage owing to reduced expression
of the recombination activating genes (Rag-1 and Rag-2). Simi-
larly, FOXO3a-deficient mice have reduced numbers of pre-B cells
(Hinman et al., 2009). Others have shown that Rag genes are direct
targets of FOXO1 and FOXO3a (Amin and Schlissel, 2008; Herzog
et al., 2008). Successful rearrangement of heavy and light chain
genes produces functional pre-BCR and mature BCR expression,
and it is likely that basal (tonic) signaling through these receptors
acts through PI3K and Akt to suppress FOXO function and turn
off Rag gene expression to achieve allelic exclusion. Consistent
with this model, mice lacking PI3K function in pre-B cells have an
elevated fraction of cells with two rearranged heavy chain alleles
(Ramadani et al., 2010).
PI3K also regulates the fate of immature B cells. Successful light
chain gene recombination at the pre-B cell stage results in expres-
sion of surface immunoglobulin (the mature BCR) and transition
to the immature B cell stage. Tonic signaling through the BCR
is required to extinguish Rag gene expression, exit the pre-B cell
stage and positively select immature B cells for further differenti-
ation (Tze et al., 2005). Three reports showed that PI3K activity is
required for basal BCR signals at the immature B cell stage, with
a selective role for p85α and p110δ isoforms (Tze et al., 2005; Llo-
rian et al., 2007; Verkoczy et al., 2007). However, the available data
indicate that PI3K suppresses Rag gene expression at this stage
via phospholipase C-γ rather than through the Akt-FOXO axis
(Verkoczy et al., 2007).
Deletion of Foxo1 with Cd19-Cre does not fully block the for-
mation of mature B cells (Dengler et al., 2008; Chen et al., 2010).
However, peripheral lymphoid organs from these mice show aber-
rant representation of B cell subsets. There is a large fraction of
B220+ cells lacking surface Ig (Dengler et al., 2008; Chen et al.,
2010), which may represent B cell progenitors escaping the bone
marrow due to altered expression of trafficking receptors. There is
also a significant increase in the marginal zone (MZ) B cell subset
(Dengler et al., 2008; Chen et al., 2010). The opposite phenotype,
a reduced MZ B cell compartment, is observed upon deletion of
PI3K catalytic (p110δ) or regulatory (p85α) subunits or inacti-
vation of both Akt1 and Akt2 (Okkenhaug et al., 2002; Suzuki
et al., 2003b; Donahue et al., 2004; Calamito et al., 2010). A sim-
ilar loss of MZ B cells occurs in mice lacking CD19, but not in
mice lacking Btk (Donahue et al., 2004). Furthermore, the MZ B
cell defect in CD19-deficient mice can be reversed by combined
deletion of Foxo1 (Chen et al., 2010). Together these observations
suggest that commitment to the MZ fate in transitional B cells
is driven by CD19 signaling through PI3K and Akt to inactivate
FOXO factors (Figure 4). The FOXO target genes that restrain MZ
B cell commitment have not been established. The Notch signaling
pathway can promote MZ B cell development even in the absence
of CD19 (Hampel et al., 2011), suggesting that FOXO proteins
might oppose Notch signaling. However, in other cellular systems
Notch and FOXO were shown to cooperate (Kitamura et al., 2007).
In the T cell lineage, a major function of FOXO proteins is to
maintain expression of the lymph node homing receptor CD62L
and other trafficking receptors necessary for proper recirculation
of quiescent cells through blood and lymphoid tissues (Fabre
et al., 2008; Kerdiles et al., 2009; Ouyang et al., 2009). Similarly,
deletion of Foxo1 in late transitional B cells (using Cd21-Cre)
impairs CD62L expression on mature B cells (Dengler et al., 2008;
Figure 3). This results in altered homing with fewer B cells detected
in the lymph nodes (Dengler et al., 2008; Chen et al., 2010). In wild-
type B cells, BCR-dependent downregulation of CD62L is partially
dependent on PI3K activity (Hess et al., 2004). FOXO activity
probably controls CD62L transcription indirectly via Krüppel-like
factors (KLFs) in B cells, as in T cells (Hart et al., 2012).
Mature B cells lacking FOXO1 show reduced surface expres-
sion of the BCR and significantly reduced BCR signaling responses
including Ca2+mobilization and phosphorylation of Akt and ERK
(Dengler et al., 2008). The mechanism for signal attenuation in the
absence of FOXO1 has not been established. However, there is a
potential connection to cancer cell lines in which PI3K/Akt inhibi-
tion leads to FOXO-dependent upregulation of receptor tyrosine
kinase expression and function (Hay, 2011). Therefore, FOXO1 in
B cells might maintain expression of signaling proteins necessary
for activation, such that BCR-PI3K-Akt signaling would inactivate
FOXO1 to trigger a built-in negative feedback mechanism. BCR
signaling through PI3K also suppresses Foxo1 expression at the
transcriptional level (Hinman et al., 2007).
At the mature B cell stage, exposure to the cytokine BAFF and
continuous expression of the surface BCR are essential to maintain
survival (Lam et al., 1997; Schiemann et al., 2001). Mouse genetic
models have shown that PI3K activity is both necessary and suffi-
cient to maintain survival of mature peripheral B cells (Srinivasan
et al., 2009; Ramadani et al., 2010). Rescue of BCR-negative cells
by expression of constitutively active PI3K or deletion of PTEN
correlates with low but detectable levels of Akt phosphorylation
(Srinivasan et al., 2009). It is likely that Akt activity has an impor-
tant function in peripheral B cell survival, as B cells lacking both
Akt1 and Akt2 show reduced fitness compared to wild-type in a
competitive repopulation assay (Calamito et al., 2010). In addi-
tion, deletion of Foxo1 partially rescues survival of BCR-negative
peripheral B cells, though the rescued cells have low CD62L expres-
sion and do not accumulate in lymph nodes (Srinivasan et al.,
2009).
Following B cell clonal selection by antigen, activated B cells
commit to one of two distinct differentiation pathways. Some
cells undergo rapid differentiation into antibody-secreting plasma
cells that secrete mostly IgM antibodies of low affinity. Other cells
commit to the germinal center (GC) fate, and surviving clones
emerge 1–2 weeks later as memory or plasma cells making high
affinity class switch antibodies (Figure 5). There is accumulating
evidence that the choice between rapid plasmablast differentiation
versus GC entry is determined by the degree of PI3K-Akt signal-
ing, and thus by the level of FOXO activity (Figure 5). Elevation
of PI3K-Akt signaling through loss of PTEN increases antibody-
secreting cell (ASC) differentiation and strongly suppresses class
switch recombination (CSR; Suzuki et al., 2003a; Omori et al.,
2006). The mechanism is directly linked to the Akt-FOXO axis,
since CSR can be restored in PTEN-deficient cells by expression
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FIGURE 4 | Model for control of marginal zone B cell development. It is
thought that transitional B cell selection into the MZ lineage is driven by
interactions of the BCR with self antigens (Wen et al., 2005). In addition,
CD19 associates with BCR signalosomes and plays a key role in recruiting
PI3K to the membrane and activating Akt following BCR engagement (Otero
et al., 2001; Wang et al., 2002; Aiba et al., 2008; Depoil et al., 2008). Genetic
studies support the model that commitment to the MZ lineage requires a
signal initiated by CD19 and propagated by PI3K (p85α/p110δ) to Akt (not
shown in this figure). This signal blocks nuclear entry of FOXO (top panel). In
the absence of CD19, the signal is interrupted and Foxo1 can program a block
to MZ development (middle panel). In the absence of Foxo1, CD19 is
dispensable for MZ B cell development (bottom panel).
of constitutively active FOXO proteins (Omori et al., 2006). Fur-
thermore, mature B cells lacking Foxo1 have severe defects in class
switching due to a failure to upregulate the gene Aicda encod-
ing the AID mutator protein (Dengler et al., 2008). In contrast,
PI3K inhibitors enhance AID expression and class switching and
oppose ASC differentiation in vitro (Omori et al., 2006). Genetic
or pharmacological blockade of the p110δ isoform of class I PI3K
specifically enhances the production of IgE (Zhang et al., 2008),
but this appears to be independent of Akt (Zhang et al., 2012). It is
important to note that whereas PI3K is essential for proliferation
triggered by BCR engagement, this requirement can be bypassed
when B cells are activated through other receptors such as TLRs,
CD40,and IL-4. Indeed,B cells stimulated with CD40L+ IL-4 pro-
liferate in the presence of PI3K inhibitors and it is these conditions
that have revealed the role for PI3K-Akt signaling in opposing CSR
(Fruman et al., 1999; Omori et al., 2006). Similarly, LPS-stimulated
B cells maintain the ability to proliferate and show elevated plas-
mablast differentiation in the presence of PI3K inhibitors (Omori
et al., 2006). Further complicating the issue, class I PI3K plays a
positive role in the ability of BCR engagement to enhance CSR
initiated by TLR ligands (Pone et al., 2012). This phenomenon
is linked to NFκB activation, and might be independent of the
Akt-FOXO axis.
In the context of T cell-dependent antibody responses, PI3K
inhibition can limit GC responses by suppressing the differenti-
ation and function of T follicular helper (Tfh) cells (Rolf et al.,
2010). PI3K function in Tfh cells might depend on Akt activation
and FOXO inhibition, since deletion of Foxo1 in T cells enhances
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FIGURE 5 | Model for control of activated B cell differentiation fate by the Akt-FOXO axis. In activated B cells, the degree of ongoing PI3K/Akt signaling
determines the relative nuclear activity of FOXO. When PI3K/Akt is high, FOXO activity is low and plasmablast differentiation is favored. When PI3K/Akt is low,
FOXO activity is elevated and a germinal center B cell fate is programmed. CSR, class switch recombination; SHM, somatic hypermutation.
Tfh differentiation and expands GCs (Kerdiles et al., 2010). This
phenotype might be an indirect effect of reduced Treg function
in mice with Foxo1-deficient T cells (Kerdiles et al., 2010), since
Tregs suppress GC responses (Alexander et al., 2011; Chung et al.,
2011; Linterman et al., 2011; Wollenberg et al., 2011). Neverthe-
less, at a global level the Akt-FOXO axis directs opposing outcomes
in T and B cells with respect to GC differentiation. In T cells,
FOXO loss enhances GCs whereas in B cells FOXO loss reduces
GC differentiation. Therefore it will be interesting to determine
how inhibitors targeting the PI3K/Akt network at different levels
will affect antibody responses to different types of pathogens and
vaccines.
RAPAMYCIN AND THE TWO mTOR COMPLEXES IN B CELLS
mTORC1 is composed of the mTOR enzyme, raptor, PRAS40,
mLST8, and DEPTOR (Figure 2; Laplante and Sabatini, 2012).
Raptor is essential for phosphorylation of mTORC1 substrates,
whereas PRAS40 and DEPTOR suppress kinase activity. The mech-
anisms of mTORC1 activation and repression are complex and
have been worked out mainly in non-lymphoid cell types. Nutri-
ents sustain mTORC1 activity through amino acid-dependent
recruitment to a complex of proteins containing Rag GTPases,
termed the Ragulator (Sancak et al., 2010), whereas glucose metab-
olism prevents the activation of AMP kinase, a negative regulator
of mTORC1. However, nutrient availability alone is not sufficient
to fully activate mTORC1; growth factor inputs (antigen receptors
and costimulatory receptors in lymphocytes) are also required.
Mitogenic signals activate mTORC1 through several mechanisms.
First, Akt and/or Erk phosphorylate and suppress the tuberous
sclerosis complex (TSC1/TSC2), relieving its GAP activity toward
the Rheb small GTPase that is an essential upstream activator of
mTORC1. Akt can also phosphorylate and inactivate PRAS40, one
of the intrinsic negative regulators of the mTORC1 complex. Pro-
duction of phosphatidic acid also occurs during cell activation
and this can contribute to mTORC1 activation. One of the sur-
prising findings of the last several years has been that mTORC1
activation in lymphocytes can occur even when PI3K/Akt activity
is undetectable. This was first observed in B cell lymphoma lines
(Wlodarski et al., 2005). Later we reported that the mechanism of
mTORC1 activation in normal mature B cells depends on the stim-
ulus (Donahue and Fruman, 2007). BCR-dependent mTORC1
activation is PI3K-dependent whereas basal and LPS-dependent
mTORC1 activity is partly PI3K-independent. Similarly, mTORC1
activity is sustained in activated T cells lacking detectable PI3K/Akt
activity (Deane et al., 2007). Other Akt-independent inputs are
likely to regulate downstream mTORC1 substrates in lympho-
cytes, as has been shown for the S6 ribosomal protein in CD8 T
cells (Salmond et al., 2009).
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mTORC2 is composed of three components essential for activ-
ity (rictor, Sin1, mLST8) along with regulatory components DEP-
TOR and PROTOR (Figure 2; Laplante and Sabatini, 2012). Based
on studies mainly done in non-lymphoid cell types, current mod-
els indicate that mTORC2 has some basal activity in cells and phos-
phorylates sites in Akt and certain PKC isoforms that are important
for folding and stability (Cybulski and Hall, 2009). Growth fac-
tor stimulation promotes increased activity of mTORC2 through
association with ribosomes (Zinzalla et al., 2011), and subsequent
mTORC2-dependent phosphorylation of the hydrophobic motif
of various AGC family kinases – most notably the S473 site on
Akt. Thus, mTORC2 acts upstream of Akt whereas mTORC1 acts
downstream of Akt. Recent data indicate that PI3K lipid products
stimulate mTORC2 activity (Gan et al., 2011; Tato et al., 2011;
Shanmugasundaram et al., 2012); the degree of basal mTORC2
activity maintained in PI3K-deficient lymphocytes is not known.
Rapamycin was first identified in a screen for natural products
with anti-fungal activity but was later shown to suppress lympho-
cyte proliferation (Sehgal et al., 1975; Martel et al., 1977; Calne
et al., 1989). Although most studies of rapamycin mechanism
have focused on T cells, it is often overlooked that rapamycin
suppresses B cell proliferation more completely. Three papers in
the early 1990s established that rapamycin has profound effects
on B cell proliferation and differentiation (Wicker et al., 1990; Kay
et al., 1991; Aagaard-Tillery and Jelinek, 1994). Pretreatment with
rapamycin completely blocked murine B cell proliferation induced
by anti-IgM (±IL-4), and reduced by 50–60% the response to
LPS (Wicker et al., 1990; Kay et al., 1991). Rapamycin prevented
B cell growth but did not impact survival (Wicker et al., 1990).
In human B lymphocytes stimulated with the polyclonal acti-
vator S. aureus, rapamycin reduced cell proliferation by 60–80%
and completely blocked differentiation into ASCs (Aagaard-Tillery
and Jelinek, 1994). Notably, rapamycin suppressed T cell receptor
(TCR)-dependent proliferation of CD4 T cells to a lesser extent
than BCR-dependent cell proliferation (Kay et al., 1991), and
more recent work showed that genetic deletion of mTOR in T
cells delays but does not block clonal expansion (Delgoffe et al.,
2009). Rapamycin does not strongly suppress CD8 T cell expansion
(Slavik et al., 2001) and actually enhances generation of memory
CD8 cells (Araki et al., 2009). Therefore, the profound effect on
BCR-driven proliferation is unusual and highlights that rapamycin
could be an effective approach for treatment of B cell-driven
autoimmune diseases. Indeed, rapamycin reduces pathogenic anti-
body accumulation and ameliorates disease in mouse models of
lupus (Warner et al., 1994; Lui et al., 2008).
The mechanisms by which rapamycin blocks B cell cycle entry
and differentiation remain unclear. mTORC1 has many substrates,
of which the most well-studied are the ribosomal S6 kinases (S6K1
and S6K2) and the eIF4E binding proteins (4EBPs; Figure 2;
Laplante and Sabatini, 2012). S6Ks promote protein and lipid
synthesis and their activity is completely dependent on mTORC1-
mediated phosphorylation (Magnuson et al., 2012). In contrast,
the phosphorylation of 4EBPs by mTORC1 is an inhibitory event
that blocks the ability of 4EBPs to suppress eIF4E function in
cap-dependent translation (Silvera et al., 2010). Overall, the phos-
phorylation of S6Ks and 4EBPs along with the suppression of
autophagy by active mTORC1 are essential for cell growth in
preparation for division. Phosphorylation of S6Ks and 4EBPs
occurs rapidly following BCR engagement (Donahue and Fru-
man, 2007), but whether these signals are required for successful B
cell growth and proliferation has not been determined. Rapamycin
strongly suppresses S6K phosphorylation in all cell types, but has
limited and variable effects on 4EBP phosphorylation (Choo et al.,
2008; Thoreen and Sabatini, 2009). Rapamycin does not acutely
inhibit mTORC2 but chronic treatment with rapamycin can sup-
press mTORC2 assembly in some cell types, including lympho-
cytes (Sarbassov et al., 2006; Lazorchak et al., 2010; Delgoffe et al.,
2011). Further work is necessary to establish whether inhibition
of mTORC1 and/or mTORC2 underlies the effects of rapamycin
in B cells. It is also possible that rapamycin has targets other than
mTOR in lymphocytes, or that a kinase-independent scaffolding
function of mTOR is disrupted upon rapamycin exposure.
Surprisingly little is known about the unique functions of
the mTOR complexes in B cells. Rapamycin is not an optimal
tool for addressing this question, since as noted above the com-
pound is only a partial inhibitor of mTORC1 (Choo et al., 2008;
Thoreen and Sabatini, 2009) and its effects on mTORC2 are depen-
dent on concentration and time of treatment (Sarbassov et al.,
2006; Lazorchak et al., 2010; Delgoffe et al., 2011). To date there
have been no publications describing the phenotype of mature
B cells lacking essential components of mTORC1 or mTORC2.
One report described a B cell-specific knockout of Sin1 but the
analysis focused on progenitor B cell development in the bone
marrow (Lazorchak et al., 2010). Interestingly, Sin1-deficient cells
showed elevated expression of IL-7 receptor and RAG proteins,
consistent with increased FOXO activity when mTORC2-Akt (and
SGK) signaling is reduced. In Sin1-deficient pre-B cells cultured
from bone marrow in vitro, expression of constitutively active
Akt2 led to FOXO1 phosphorylation and reduced RAG expres-
sion (Lazorchak et al., 2010). Akt2 might not be essential for
FOXO regulation in vivo, as B cell development is not impaired in
mice lacking Akt2 or in chimeric mice lacking both Akt1 and Akt2
in B cell progenitors (Calamito et al., 2010). Notably, prolonged
rapamycin treatment suppressed mTORC2-dependent Akt phos-
phorylation leading to elevated expression of FOXO1 and RAG
proteins (Lazorchak et al., 2010).
Although B cells lacking mTORC1 function have not yet been
described, one study analyzed the consequences of B cell-specific
loss of the negative regulator TSC1 (Benhamron and Tirosh,
2011). As expected, mTORC1 activity was increased as judged
by phosphorylation of S6 protein downstream of S6Ks. A striking
phenotype was a reduced percentage of MZ B cells. The most likely
explanation is that elevated mTORC1 activity in transitional B cells
engages negative feedback loops that reduce activity of upstream
PI3K/Akt signaling. Well-established negative feedback mecha-
nisms include S6K-dependent phosphorylation of insulin receptor
substrate (IRS) proteins and mTORC1-dependent phosphoryla-
tion of the adaptor protein Grb10 (Yea and Fruman, 2011; Laplante
and Sabatini, 2012). As discussed earlier, reduced PI3K/Akt activity
is known to diminish MZ B cell development. However, the status
of PI3K/Akt signaling in TSC1-deficient B cells was not assessed
in this study.
An interesting report described the phenotype of mice with
a hypomorphic allele of Mtor that reduces mTOR protein
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expression and diminishes the activity of both mTORC1 and
mTORC2 (Zhang et al., 2011). These mice have a greatly reduced
number of peripheral B cells and a partial block in early develop-
ment at the large pre-B cell stage. Whether this block is associated
with altered FOXO function or RAG expression was not investi-
gated. B cells with reduced mTOR expression have greatly impaired
proliferative responses to anti-IgM or anti-CD40, whereas the
LPS response is largely intact. Curiously, B cells from these mice
display elevated phosphorylation of Akt on S473 following LPS
stimulation. This correlates with increased expression of DNA-
PK, an alternative kinase for Akt-S473, and can be reduced by
a selective DNA-PK inhibitor. These findings highlight that the
effect of mTOR inhibition on Akt-S473 phosphorylation is highly
context-dependent. Whether chronic treatment with mTOR cat-
alytic inhibitors would also lead to DNA-PK upregulation in B
cells is not known.
Akt AND mTOR IN B CELL MALIGNANCIES
Activation of the PI3K/Akt/mTOR signaling network is a common
feature of most human cancers (Engelman et al., 2006; Liu et al.,
2009; Hanahan and Weinberg, 2011). Malignancies of B cell origin
are no exception. Many groups have documented high basal levels
of Akt and mTOR activation in B cell leukemias, B cell lymphomas,
and multiple myeloma (MM) cells. For example, the BCR-ABL
oncoprotein strongly activates PI3K/Akt signaling and mTOR
activity in Philadelphia Chromosome-positive (Ph+) leukemias
(Skorski et al., 1997; Kharas et al., 2008; Janes et al., 2010). mTOR
is activated in a Syk-dependent manner in follicular lymphoma
cells (Leseux et al., 2006; Fruchon et al., 2012). In diffuse large B
cell lymphoma (DLBCL), the microRNA miR-155 is often overex-
pressed leading to reduced amounts of the SHIP phosphatase that
can dephosphorylate the 5’-phosphate of PIP3 (Pedersen et al.,
2009). The activated B cell subset of DLBCL displays constitu-
tive Akt signaling through chronic active BCR signaling (Davis
et al., 2010). Interestingly, a fraction of MM tumors shows elevated
expression of DEPTOR, an endogenous inhibitor of mTORC1 and
mTORC2 (Peterson et al., 2009). In this case, DEPTOR appears to
be important for limiting mTORC1-dependent negative feedback
on PI3K/Akt activity.
The central role of PI3K/Akt/mTOR signaling in B cell neo-
plasms has led many investigators to test the efficacy of small
molecule inhibitors of this network. Proof-of-concept was pro-
vided first by clinical trials showing significant responses to tem-
sirolimus (CCI-779; an orally active rapamycin analog) in patients
with mantle cell lymphoma (Hess et al., 2009). Such rapalogs
have shown generally more limited success in other clinical trials
of leukemia, lymphoma, and myeloma (Kelly et al., 2011). ATP-
competitive compounds that target of the active site of mTOR
show more promise. In preclinical studies, dual-targeted agents
that directly inhibit both PI3K and mTOR (e.g., PI-103, NVP-
BEZ235) have shown efficacy in Ph+ pre-B cell acute leukemia
(Kharas et al., 2008), chronic lymphocytic leukemia (CLL; Nieder-
meier et al., 2009), various B cell lymphomas (Bhatt et al., 2010;
Bhende et al., 2010), and MM (Baumann et al., 2009).
Selective mTOR kinase inhibitors appear to be as effective as
panPI3K/mTOR inhibitors in models of Ph+ leukemia (Carayol
et al., 2010; Janes et al., 2010) and MM (Maiso et al., 2011),
with lesser toxicity (Janes et al., 2010). However, there might be
some B cell malignancies in which dual PI3K/mTOR inhibition
or PI3K inhibition alone might be most effective. Recent stud-
ies have revealed that selective inhibition of the p110δ isoform
of PI3K produces remarkable clinical responses in CLL patients
(Fruman and Rommel, 2011). Similarly, Btk inhibitors in clinical
development have shown great promise in clinical trials of CLL
treatment (Winer et al., 2012). Thus, the connection of PI3K and
Btk is not limited to BCR-mediated activation of normal B cells,
but seems to represent a key signaling axis for CLL cell prolifera-
tion, survival, and migration. Although antibody-mediated B cell
depletion (anti-CD20; rituximab) often provides benefit for the
treatment of B cell malignancies, PI3K/Btk-targeted small mole-
cules might have some advantages. Such agents would be more
rapidly reversible than long-lived antibodies upon cessation of
treatment, allowing prompt resolution of adverse immunosup-
pressive effects. Small molecule orally active compounds might
also be more convenient and less expensive to administer. It is
also possible that PI3K/Btk inhibitors will be useful as adjuncts
to rituximab, as suggested by preliminary reports of combination
trials in non-Hodgkin’s lymphoma (Fruman and Rommel, 2011;
Winer et al., 2012). Ultimately, the optimal PI3K/mTOR inhibitors
and combinations for different malignancies will require careful
comparison of efficacy and tolerability in clinical trials.
SUMMARY AND FUTURE DIRECTIONS
In B cells activated through BCR crosslinking, treatment with
either PI3K inhibitors or rapamycin profoundly blocks B cell pro-
liferation. This suggests a direct function of mTOR downstream
of PI3K in BCR signaling. However, subsequent studies of PI3K,
Akt, and mTOR signaling in B cells have led to a number of sur-
prises. Whereas rapamycin completely blocks differentiation of
B cells stimulated with TLR ligands or T cell-derived helper fac-
tors (i.e., CD40L+ IL-4), PI3K inhibition has the distinct effect
of enhancing CSR while suppressing terminal differentiation to
plasma cells. Deletion of Foxo1, which might have been predicted
to lower the threshold for B cell activation, actually attenuates
B cell proliferation and differentiation. We propose a model in
which two key downstream PI3K effector arms in B cells have
distinct functions. In simple terms, the Ca2+ signalosome drives
proliferation, whereas the Akt-FOXO axis controls differentiation.
Following antigen recognition, BCR signaling through PI3K leads
to signalosome assembly to drive cell cycle progression primarily
through NFκB activation (Figure 1). The subsequent differentia-
tion path of the activated B cell is controlled by the kinetics and
magnitude of PI3K activation through the BCR and other sig-
nals including TLR engagement and T cell help (Figure 5). High
PI3K/Akt activity suppresses FOXO function to promote rapid
production of plasma cells secreting mainly IgM. Low PI3K/Akt
activity allows FOXO function to be re-established, and programs
the cell to express AID and commit to the GC B cell fate. This
mechanism makes sense in that it allows the host to tailor the
antibody response to the antigen. When there is a high affinity or
abundant antigen, the goal is to make antibodies quickly. This is
achieved through sustained PI3K/Akt signaling that drives plasma
cell differentiation. When the antigen is of low affinity or not
abundant, eradication of the antigen requires high affinity class
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switched antibodies. This would be achieved because the reduced
antigen-derived signals limit PI3K/Akt activity, allowing FOXO
factors to program the GC B cell fate.
A question that arises from this model is why mTOR inhibition
with rapamycin is such a potent inhibitor of both B cell prolifer-
ation and differentiation, regardless of the stimulus. This finding
suggests an essential function of mTORC1 in these processes. One
possibility is that mTORC1 activity is required in B cells and that
sufficient mTORC1 function is maintained even when PI3K/Akt
activity is suppressed. However, the mTORC1 substrates whose
function is essential in B cells have not been established. Future
work should investigate the functions of S6Ks, 4EBPs, and other
mTORC1 substrates in B cells. Complicating matters, we have
shown that ATP-competitive mTOR kinase inhibitors have dis-
tinct effects on B cells compared to rapamycin. At concentrations
that strongly suppress phosphorylation of mTORC1 and mTORC2
substrates, mTOR kinase inhibitors only partially reduce prolif-
eration of activated mature splenic B cells (Janes et al., 2010).
Ongoing work in our laboratory is focused on resolving this
paradox.
Another key question to be resolved is whether Akt in B cells has
other important substrates besides FOXO transcription factors.
The activation of PI3K and Akt has been linked to increased gly-
colysis in activated B cells (Doughty et al., 2006), but the relevant
components linking Akt to metabolic changes have not been fully
worked out. At the organismal level, Akt2 is primarily responsible
for insulin/glucose homeostasis whereas Akt1 has a more dom-
inant role in cell proliferation and differentiation (Fayard et al.,
2010). Whether a similar division of labor occurs in B cells will be
interesting to determine. It is also worth testing whether mTORC2
and its non-Akt substrates regulate B cell motility and chemotaxis,
as reported in other systems (Masri et al., 2007; Gulhati et al.,
2011). Identification of the Akt and mTOR substrates that control
various aspects of B cell function could lead to novel targets for
therapeutic intervention in immune diseases and cancer.
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